EN CN


In Vitro Safety Assessment

Return

Sedation Off Target Portfolio

CNS Safety Pharmacology

Sedation is one of the most common adverse drug reactions associated with CNS drugs. This sedation off-target portfolio is designed to identify ion channels and GPCRs associated with sedative side effects, helping reduce undesired CNS depression during drug development.

The panel includes targets that regulate neuronal excitability, synaptic transmission and neurotransmitter release, all of which may contribute to sedation as an off-target effect.

Mechanistic Coverage

Key Targets in the Portfolio

Ion Channels

GABA Receptors (GABAα1β2γ2, GABAα1β3γ2): Overactivation of GABAergic transmission can increase CNS inhibition and cause sedation.

Potassium Channels (KCNQ2/3, BK, IK): Hyperpolarization caused by potassium-channel activation can suppress neuronal activity and contribute to sedation.

Voltage-Gated Calcium Channels (Cav1.3, Cav2.1, Cav2.2): These channels regulate neurotransmitter release; inhibition may dampen synaptic activity and lead to sedative effects.

Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels (HCN1, HCN2): Reduced activity of these channels can suppress wakefulness and promote sedation.

GPCRs · G Protein-Coupled Receptors

Histamine H1 Receptors: Blockade of H1 receptors is a well-known cause of sedation, commonly observed with antihistamines.

5-HT1A and 5-HT2 Receptors: Modulation of serotonergic signaling can influence arousal and sleep–wake cycles.

Dopamine D2 Receptors: Inhibition can suppress dopamine signaling, reduce alertness and induce sedation.

Adrenergic α2 Receptors: Activation can dampen CNS arousal pathways and contribute to sedative effects.

Muscarinic Acetylcholine Receptors (M1, M2): Antagonism of these receptors can reduce arousal and result in sedation.

Safety Profiling

Sedation Off-Target Portfolio

The Sedation Off-Target Portfolio provides a comprehensive framework for screening ion channels and GPCRs implicated in sedative side effects. By identifying and characterizing these off-target interactions, the panel supports the development of safer and more selectively targeted therapeutics.


Contact Us

We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.

We are a CRO service organization, not a hospital




Get a quote

Go top